Mirion Earnings Preview: Nuclear Growth and Medical Tech in Focus

ATLANTA, GA – January 22, 2026 – Investors and industry analysts are turning their attention to Mirion Technologies (NYSE: MIR) as the company prepares to announce its fourth-quarter and full-year 2025 financial results. The radiation safety and science leader will release the much-anticipated report after the market closes on Tuesday, February 10, 2026, followed by a conference call with management the next morning at 11:00 am ET.

The announcement is poised to provide a comprehensive look at the company's performance throughout 2025, a year marked by strategic acquisitions and significant contract wins, particularly in the resurgent nuclear energy sector. Stakeholders will be closely examining the results to gauge Mirion's financial health and its trajectory heading into 2026.

Setting a High Bar with Strong 2025 Momentum

Mirion enters this reporting period on a wave of positive momentum, having posted strong results in its third quarter of 2025. In its last earnings report on October 28, 2025, the company announced a 7.9% year-over-year revenue increase to $223.1 million, with a notable improvement in profitability. GAAP net income swung to a positive $3.1 million, a stark contrast to the $14.0 million loss reported in the same quarter of the previous year.

This solid performance prompted the company to reaffirm its ambitious full-year 2025 guidance. Mirion projected total revenue growth between 7.0% and 9.0%, with organic growth expected in the range of 4.5% to 6.0%. The company also guided for Adjusted EBITDA between $223 million and $233 million, with an adjusted earnings per share (EPS) of $0.48 to $0.52. Furthermore, management raised the lower end of its Adjusted Free Cash Flow guidance to a range of $100 million to $115 million, signaling confidence in its operational efficiency and cash generation capabilities.

Meeting these targets, which were initially set based on strong 2024 performance and later updated, will be a key benchmark for success. The fourth-quarter results must be robust to close out the year within these guided ranges, and the upcoming report will be the ultimate scorecard for the company's 2025 strategy.

Analyst Optimism and Key Questions

Wall Street has maintained a largely positive outlook on Mirion, with a consensus "Buy" rating from analysts covering the stock. The average 12-month price target sits near $28.29, reflecting confidence in the company’s market position and growth prospects. Some firms have set even higher expectations, with JPMorgan assigning a $34 price target.

However, an interesting point of focus for the upcoming release is the gap between the company's own guidance and prevailing analyst estimates. While Mirion projects an Adjusted EPS of up to $0.52 for the full year, the average sell-side analyst forecast has hovered closer to $0.39. The February 10th report will resolve this discrepancy and could trigger a re-evaluation from market watchers depending on where the final number lands.

Mirion's stock performance has reflected this optimistic sentiment, trading in a wide range over the past year from a low of $12.00 to a high of $30.28. The stock has recently traded above its 50-day and 200-day moving averages, indicating positive technical momentum. While a late 2025 sale of shares by a company director, Lawrence D. Kingsley, was noted by market participants, the broader analyst consensus remains bullish on the company's fundamental strengths.

Nuclear Renaissance Fuels Strategic Wins

A significant portion of Mirion's recent success can be attributed to its Nuclear & Safety group, which has effectively capitalized on renewed global investment in nuclear power. The segment saw orders grow by an impressive 21% in the third quarter of 2025, driven by both new projects and upgrades to existing facilities.

Two major contracts in the second half of 2025 underscored the company's strong positioning. Mirion secured an approximately $10 million order related to a small modular reactor (SMR) new-build project, a crucial win in the next-generation nuclear technology space. This was followed by a substantial order valued at approximately $55 million to support the installed reactor base in Asia, demonstrating the company's ability to secure large-scale, long-term business in key international markets.

Investors will be keen to hear management's commentary on the sustainability of this trend during the conference call. Questions will likely focus on the pipeline for future nuclear projects, the outlook for the SMR market, and how Mirion plans to leverage its technology to maintain its leadership position as countries worldwide pursue energy independence and decarbonization goals.

Medical Segment Growth and Future Outlook

While the nuclear segment has captured headlines, Mirion's Medical group remains a vital and growing component of its business. This division provides essential solutions across Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging, helping to ensure safety and enhance the delivery of care in critical healthcare settings.

Organic growth in the medical segment has been steady, reflecting persistent demand for quality assurance and safety in oncology and medical diagnostics. The company's strategic vision for this division was further clarified with the acquisition of Paragon Energy Solutions, which was completed on December 1, 2025. This acquisition is expected to contribute to Mirion's revenue and expand its capabilities.

The upcoming earnings call will be the first major opportunity for management to discuss the integration of Paragon and elaborate on its strategic importance. Analysts will be listening for details on expected synergies, the impact on the 2026 financial outlook, and how the acquisition strengthens Mirion's competitive moat in the medical technology landscape.

As stakeholders await the financial disclosures, the narrative for Mirion is one of a company firing on multiple cylinders. The February 11th conference call will provide the crucial color behind the numbers, offering insights into management's strategy for navigating the opportunities in both the nuclear and medical fields and setting the tone for investor expectations for the year ahead.